Friday, February 23, 2018

Gabriel Pardo, MD, Director, OMRF Multiple Sclerosis Center of Excellence

**Title:** Multiple Sclerosis Treatment Paradigms: Selection, Sequencing and Success

**ACPE UAN:** #0128-9999-18-001-L01-P

**CPE:** 1.0 contact hour / Knowledge based CPE activity

**Objectives:**
1. Describe the efficacy and safety data of established and emerging MS disease-modifying therapies (DMTs).
2. Define the evidence and strategies for appropriate patient selection of different DMTs.
3. List evidence-based criteria for treatment changes based on patient response.
4. Explain the safety an immunological consideration in selection and sequencing of DMTs.

Sara Noble, PharmD, MPH, DUR Coordinator, Mississippi Medicaid & Dr. Laureen Biczak, DO, Medical Director, Change Healthcare

**Title:** Mississippi Medicaid’s Complex Pharmacy Care (CPC) Program - Challenges and Opportunities

**ACPE UAN:** #0128-9999-18-002-L04-P

**CPE:** 0.5 contact hour / Knowledge based CPE activity

**Objectives:**
1. Explain the program’s origin and funding from the state’s perspective.
2. Outline the differences in a MTM vs. a CPC program.
3. Identify the need and the variables encountered in initiating the CPC program.
4. Describe issues encountered in managing the daily operations.
5. Explain the CPC program impact in its first year of operation.

Dr. Laureen Biczak, DO, Medical Director, Change Healthcare

**Title:** Smart Bugs, New Drugs - Update on Antimicrobials

**ACPE UAN:** #0128-9999-18-003-L01-P

**CPE:** 1.0 contact hour / Knowledge based CPE activity

**Objectives:**
1. Describe the antimicrobial “innovation gap”.
2. List at least 3 pathogens that the World Health Organization lists as either “critical” or “high priority” pathogens in trying to guide new drug development.
3. Identify at least 2 antibiotics that have become available in the last 5 years and describe at least 1 key aspect that differs from prior therapies.
4. Explain key steps that a clinician should take when prescribing an empiric antimicrobial agent.

Afzal Mistry, PharmD, Clinical Programs Director, NorthStar Healthcare Consulting

**Title:** Medical ProDUR Program for Georgia Medicaid

**ACPE UAN:** #0128-9999-18-004-L04-P

**CPE:** 0.5 contact hour / Knowledge based CPE activity

**Objectives:**
1. Describe the prospective drug utilization review (ProDUR) process for provider-administered drugs.
2. Identify unique obstacles for provider-administered ProDUR programs.
3. Review methods of utilizing Outpatient Pharmacy Program rebates for provider-administered drugs.

Cynthia Denemark, RPh, Director of Pharmacy Services, Dept. of Health and Human Services, State of Delaware

**Title:** DUR Then & Now!

**ACPE UAN:** #0128-9999-18-005-L04-P

**CPE:** 0.5 contact hour / Knowledge based CPE activity

**Objectives:**
1. Describe the steps needed to integrate HCPCS codes into the NCPDP alerts.
2. Evaluate one approach to bridging the gap between a prospective and retrospective DUR program.
3. Identify the most meaningful alert and medications to apply concurrent DUR activities.


**Title:** Department of Justice and the Opioid/Heroin Crisis  
**ACPE UAN:** #0128-9999-18-006-L03-P  
**CPE:** 1.0 contact hour / Knowledge based CPE activity  
**Objectives:**
1. Explain the Department of Justice’s multi-pronged approach to the opioid/Heroin Crisis, including prevention, enforcement and treatment.
2. Explain the basis for federal prosecution of professionals under the Controlled Substance Act.
3. Describe the federal Sentencing Guidelines and how they are applied for controlled substance violations.

**Carl Jeffery, PharmD**, Senior Manager, Account Mgmt, OptumRx

**Title:** Clinical PEARL – Nevada Medicaid Opioid Quantity Limit Implementation  
**ACPE UAN:** #0128-9999-18-007-L04-P  
**CPE:** 0.5 contact hour / Knowledge based CPE activity  
**Objectives:**
1. Describe how the specific quantity limits were derived and implemented in the fee for service Medicaid program.
2. List the three limitations Nevada Medicaid currently has in place for opioids quantity limits.
3. Explain how patients can get opioid amounts exceeding the maximum.
4. Describe the public communication process.
5. List the lessons learned.

**Bethany Holderread, PharmD**, Clinical Coordinator, Pharmacy Management Consultants

**Title:** PEARL Oklahoma’s Experience with Value-Added Programs  
**ACPE UAN:** #0128-9999-18-008-L04-P  
**CPE:** 0.5 contact hour / Knowledge based CPE activity  
**Objectives:**
1. Define alternative payment model.
2. List the two general types of APMs.
3. Identify 3 barriers to value based contracts in Medicaid.

**Brendan Joyce, PharmD**, Pharmacy Administrator, North Dakota Medicaid

**Title:** State Roundtable - State Medicaid Programs - Part 1  
**ACPE UAN:** #0128-9999-18-009-L04-P  
**CPE:** 1.25 contact hours / Knowledge based CPE activity  
**Objectives:**
1. Review retroDUR methodologies, processes, and outcomes of State Medicaid DUR initiatives.
2. Identify environmental factors that contribute to successes and failures of State Medicaid programs medication management initiatives.
3. Describe proposals for DUR initiatives based upon the proposal phase, implementation phase, program delivery and outcome evaluation phase.

**Saturday, February 24, 2018**

**Thomas Frank, PharmD, BCPS**, Frank Medical Consulting

**Title:** New Drugs 2018  
**ACPE UAN:** #0128-9999-18-010-L01-P  
**CPE:** 2.0 contact hours / Knowledge based CPE activity  
**Objectives:**
1. Identify new trends in drug development.
2. List indications, pharmacology, adverse effects, and dosing.
3. Explain the importance of these products.
4. Describe the economic implication of these choices.
5. Review products in the short-term pipeline.
Christopher Shaffer, PharmD, MS, BCPS, Associate Dean & Asst. Professor, Dept. of Pharmacy Practice, Nebraska Medical Center

**Title:** Personalized Medicine  
**ACPE UAN:** #0128-9999-18-011-L01-P  
**CPE:** 1.0 contact hours / Knowledge based CPE activity  
**Objectives:**
1. Define Personalized Medicine.
2. Identify specific examples of gene-drug interactions and their impact on clinical care.
3. Describe genetic diagnostic testing approaches and its impact on healthcare.
4. Review opportunities and barriers related to the implementation of Personalized Medicine.

Maria M. Lowe, PharmD, BCPS, Health Data & Drug Information Clinical Specialist, PatientsLikeMe  

**Title:** Pipeline Preview 2018  
**ACPE UAN:** #0128-9999-18-012-L01-P  
**CPE:** 1.5 contact hours / Knowledge based CPE activity  
**Objectives:**
1. Describe recent trends in the FDA approval process.
2. Review emerging pipeline agents with currently available therapeutic options.
3. List the expected generic availability of commonly used agents over the next two years.

Brendan Joyce, PharmD, Pharmacy Administrator, North Dakota Medicaid  

**Title:** State Roundtable - State Medicaid Programs - Part 2  
**ACPE UAN:** ACPE UAN: #0128-9999-18-013-L04-P  
**CPE:** 1.25 contact hours / Knowledge based CPE activity  
**Objectives:**
1. Review retroDUR methodologies, processes, and outcomes of State Medicaid DUR initiatives.
2. Identify environmental factors that contribute to successes and failures of State Medicaid programs medication management initiatives.
3. Describe proposals for DUR initiatives based upon the proposal phase, implementation phase, program delivery and outcome evaluation phase.

The 2018 ADURS Symposium is designed for pharmacists specializing in medication utilization within State Medicaid programs and is sponsored by the American Drug Utilization Review Society (ADURS) and the Nebraska Council for Continuing Pharmacy Education (NCCPE). NCCPE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Credit for courses must be earned by the participant. Participants will earn up to 12.5 contact hours of continuing pharmacy education (CPE) credits for attendance of the entire symposium.

In order to earn CPE credits, the participant must complete an on-line educational evaluation form for each CPE session they attend within 15 days from the end of the symposium. The evaluation will collect birthdates (MMDD) and NABP e-Profile ID numbers (to receive CPE credits, the attendee must have an NABP e-Profile ID number). For more information about NABP e-Profile IDs, please see http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service/. ACPE CPE numbers and speaker objectives can be found in the program schedule. CPE credits will be sent to your NABP e-Profile within 45 days of the program date. For questions about CPE credits, please call NCCPE at (402) 420-1500.